131.14
0.19%
0.25
After Hours:
131.00
-0.14
-0.11%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $131.14, with a volume of 2.59M.
It is up +0.19% in the last 24 hours and up +0.78% over the past month.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$130.89
Open:
$133.76
24h Volume:
2.59M
Relative Volume:
0.69
Market Cap:
$583.84B
Revenue:
$37.42B
Net Income/Loss:
$13.05B
P/E Ratio:
54.47
EPS:
2.4077
Net Cash Flow:
$9.51B
1W Performance:
-5.76%
1M Performance:
+0.78%
6M Performance:
+5.12%
1Y Performance:
-31.43%
Novo Nordisk Adr Stock (NVO) Company Profile
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-30-24 | Initiated | Goldman | Buy |
Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Neutral |
Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-02-23 | Initiated | Argus | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-28-22 | Downgrade | UBS | Neutral → Sell |
Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-25-22 | Downgrade | Liberum | Hold → Sell |
Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Hold |
Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
May-11-20 | Downgrade | UBS | Buy → Neutral |
May-04-20 | Initiated | Cowen | Market Perform |
Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth. - The Motley Fool
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? - The Motley Fool
Novo Nordisk ADR [NVO] Stock trading around $130.89 per share: What’s Next? - The DBT News
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem - The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts - Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern - Benzinga
Battle Over Compounded Weight-Loss Medications - Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know. - The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors? - The Motley Fool
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race - Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now - The Motley Fool
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock - The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now - The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits - Benzinga
Experts predict Novo Nordisk ADR’s (NVO) current quarter earnings growth rate - US Post News
How does Novo Nordisk ADR (NVO) change from a tortoise to a hare? - SETE News
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients - Benzinga
Novo Nordisk's Massive GLP-1 Growth Reflects the Firm's Wide Moat in Cardiometabolic Diseases - Morningstar
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock - The Motley Fool
Global GLP-1 Analogues Market Report 2024-2032: Market Expansion Driven by Innovation and Efficacy in Diabetes and Obesity Treatment - GlobeNewswire Inc.
Wall Street Analyst Initiated Novo Nordisk ADR [NVO]. What else is Wall St. saying - The DBT News
Novo Nordisk ADR (NVO) Stock: From Low to High in 52 Weeks - The InvestChronicle
Should Novo Nordisk ADR (NYSE: NVO) Investors Be Concerned? - Stocks Register
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble? - The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $1,000 - The Motley Fool
Perhaps timely catching Novo Nordisk ADR (NVO) would be a good idea - SETE News
NVO’s Market Whiplash: 29.57% YTD Rise, 0.57% Rise in 30 Days - The InvestChronicle
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing - GlobeNewswire Inc.
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945? - The Motley Fool
Why Eli Lilly Topped the Market on Tuesday - The Motley Fool
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - GlobeNewswire Inc.
Hemophilia Market Size to Surpass US$ 23.99 Billion by 2033, The Brainy Insights - GlobeNewswire Inc.
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond - The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived - The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years - The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year - The Motley Fool
Is Madrigal Pharmaceuticals Stock a Buy? - The Motley Fool
3 Fantastic Growth Stocks to Buy in August - The Motley Fool
Could Viking Therapeutics Become the Next Novo Nordisk? - The Motley Fool
Is Hims & Hers Health the Best Growth Stock for You? - The Motley Fool
Are Smart Investors Making the Right Decision? Novo Nordisk ADR (NVO) - SETE News
Will Novo Nordisk ADR (NVO) beat or miss earnings estimates this quarter? - US Post News
Novo Nordisk ADR [NVO] moved up 2.34: Why It’s Important - The DBT News
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater - The Motley Fool
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer) - The Motley Fool
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors? - The Motley Fool
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. George L. Bakris - GlobeNewswire Inc.
Novo Nordisk ADR: Navigating Market Fluctuations with a 447.00B Market Cap - The InvestChronicle
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy? - The Motley Fool
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock - The Motley Fool
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk - The Motley Fool
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):